Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China · Delayed Price · Currency is CNY 5.40
-0.22 (-3.91%)
At close: Sep 9, 2026
SHA:688373 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 164.25 | 141.69 | 130.27 | 90.78 | 48.21 | 7.66 |
Other Revenue | 0.08 | 0.09 | - | - | - | - |
| 164.33 | 141.77 | 130.27 | 90.78 | 48.21 | 7.66 | |
Revenue Growth | 20.39% | 8.83% | 43.51% | 88.31% | 529.33% | - |
Cost of Revenue | 23.34 | 21.53 | 22.41 | 16.7 | 8.82 | 0.76 |
Gross Profit | 141 | 120.24 | 107.87 | 74.08 | 39.38 | 6.9 |
Selling, General & Admin | 146.76 | 152.73 | 176.79 | 168.57 | 146.18 | 124.38 |
Research & Development | 140.69 | 213.93 | 368.56 | 344.86 | 150.39 | 151.76 |
Other Operating Expenses | 0.28 | 0.54 | 0.41 | 0.3 | 0.14 | 0.03 |
Operating Expenses | 287.9 | 367.45 | 546.53 | 514.06 | 296.9 | 276.2 |
Operating Income | -146.91 | -247.21 | -438.66 | -439.98 | -257.52 | -269.3 |
Interest Expense | -12.73 | -12.89 | -11.15 | -10.14 | -8.82 | -5.23 |
Interest & Investment Income | 1.86 | 2.41 | 2.37 | 2.19 | 4.4 | 2.39 |
Currency Exchange Gain (Loss) | 3.69 | 3.95 | -4.52 | 0.02 | -5.59 | -0.29 |
Other Non Operating Income (Expenses) | 0.41 | -0.47 | -1 | -0.13 | 0.34 | -0.4 |
EBT Excluding Unusual Items | -153.67 | -254.22 | -452.96 | -448.03 | -267.19 | -272.82 |
Gain (Loss) on Sale of Investments | 4.6 | 6.49 | 17.08 | 33.34 | 18.49 | 10.53 |
Gain (Loss) on Sale of Assets | -0 | 0 | 0.03 | 0 | 0.49 | -0.02 |
Other Unusual Items | 1.9 | 2.16 | 1.34 | -0.46 | 27.92 | 36.08 |
Pretax Income | -147.17 | -245.57 | -434.51 | -415.15 | -220.29 | -226.23 |
Income Tax Expense | -6.67 | -3.95 | 6.21 | 5.97 | 0.01 | 0.04 |
Net Income | -140.5 | -241.61 | -440.72 | -421.12 | -220.3 | -226.27 |
Net Income to Common | -140.5 | -241.61 | -440.72 | -421.12 | -220.3 | -226.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 636 | 653 | 658 | 656 | 580 | 526 |
Shares Outstanding (Diluted) | 636 | 653 | 658 | 656 | 580 | 526 |
Shares Change | -4.13% | -0.73% | 0.33% | 13.09% | 10.17% | 106.16% |
EPS (Basic) | -0.22 | -0.37 | -0.67 | -0.64 | -0.38 | -0.43 |
EPS (Diluted) | -0.22 | -0.37 | -0.67 | -0.64 | -0.38 | -0.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -116.25 | -210.73 | -448.1 | -336.74 | -252.18 | -203.89 |
Free Cash Flow Per Share | -0.18 | -0.32 | -0.68 | -0.51 | -0.43 | -0.39 |
Gross Margin | 85.80% | 84.81% | 82.80% | 81.61% | 81.70% | 90.08% |
Operating Margin | -89.39% | -174.37% | -336.72% | -484.69% | -534.19% | -3515.62% |
Profit Margin | -85.50% | -170.42% | -338.31% | -463.91% | -456.99% | -2953.91% |
Free Cash Flow Margin | -70.74% | -148.64% | -343.97% | -370.96% | -523.13% | -2661.81% |
EBITDA | -144.34 | -244.87 | -436.4 | -437.97 | -256.22 | -268.75 |
EBITDA Margin | -87.83% | -172.72% | - | - | - | - |
D&A For EBITDA | 2.57 | 2.34 | 2.26 | 2.02 | 1.29 | 0.55 |
EBIT | -146.91 | -247.21 | -438.66 | -439.98 | -257.52 | -269.3 |
EBIT Margin | -89.39% | -174.37% | - | - | - | - |
Revenue as Reported | 164.33 | 141.77 | 130.27 | 90.78 | 48.21 | 7.66 |